drugset / Trial / NCT03555916
Botulinum Toxin Injections for Oral Neuropathic Pain
Phase 3
Completed
43 enrolled
Assistance Publique - Hôpitaux de Paris
Karolinska Institutet · collabUniversity of Aarhus · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
Peripheral painful traumatic trigeminal neuropathy (PPTTN) are poorly relieved by existing treatments which in addition induce many adverse effects. BTX, which blocks the exocytosis of neurotransmitters, can be captured by axonal retrograde transport in primary nociceptive neurons. Injected in the painful area, it might therefore inhibit the release of algogenic neurotransmitters, at both the peripheral and central levels and thus reduce pain. One study reported such an effect in neuropathic spinal pain. A recent study reported an analgesic effect in trigeminal neuralgia.
Timeline
- Start
- 2019-04-04
- Primary completion
- 2022-07-19
- Completion
- 2022-11-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Botulinum toxin type A | Protein / enzyme biologic | 50 iu | Other |